Hepatocellular carcinoma in patients listed for liver transplantation: Current and future allocation policy and management strategies for the individual patient
| Autor: | Thor Johnson, Eric M Nordstrom, W. Thomas Purcell, Michael A. Zimmerman, Joel P. Wedd, Scott W. Biggins, Janette D. Durham, Trevor L. Nydam |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Oncology
Transplantation medicine.medical_specialty Carcinoma Hepatocellular Cirrhosis Hepatology business.industry Patient Selection medicine.medical_treatment Liver Neoplasms Tumor burden Liver transplantation medicine.disease digestive system diseases Liver Transplantation Liver graft Hepatocellular carcinoma Internal medicine medicine Humans Surgery In patient business neoplasms |
| Zdroj: | Liver Transplantation. 21:1543-1552 |
| ISSN: | 1527-6473 1527-6465 |
| DOI: | 10.1002/lt.24356 |
| Popis: | Liver transplantation can provide definitive cure for patients with cirrhosis and hepatocellular carcinoma (HCC) when used appropriately. Advances in the management of HCC have allowed improved control of HCC while waiting for liver transplantation and new approaches to candidate selection particularly with regard to tumor burden and downstaging protocols. Additionally, there have been recent changes in allocation policy related to HCC in the U.S. that cap the HCC MELD exception at 34 points and implement a 6-month delay in a HCC MELD exception. This review examines the U.S. liver transplant allocation policy related to HCC, comprehensively details locoregional therapy options in HCC patients awaiting liver transplantation, and considers the impact of an increasing burden of HCC on future liver graft allocation policy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text